QIAGEN at ECCMID 2018

See HPV differently

A breakthrough solution in cervical cancer screening

What if you could see if HPV was transforming cells and turning them cancerous?

Cervical cancer is the second most common cancer among women aged 15 to 44, affecting more than 500,000 women a year. Fortunately, it is almost 100% preventable through advanced screening and early detection of precancer before the disease becomes a danger to a patient’s life or reproductive health.

QIAsure, the new reproductive health solution from QIAGEN, is a cervical cancer triage solution that lets clinicians see what’s happening at a molecular level to determine whether cervical cells are actively transforming into cancer. This innovative test objectively detects the presence of biomarkers associated with cervical precancer and cancer in the PCR lab, using the same sample from an HPV or liquid-based cytology test. Whether the result is positive or negative, QIAsure can provide peace of mind for patients so they can live their lives safe, confident, and sure of their reproductive health.

Download the brochure to learn more about how QIAsure can give you molecular insight into whether an HPV infection is actively transforming cervical cells into cancer.

download brochure

 

Visit us at the QIAGEN booth at ECCMID to talk to our QIAsure experts!

Visit us at ECCMID 2018, booth #36

Register for Expert Talks
For up-to-date licensing information and product-specific disclaimers, see the respective QIAGEN kit handbook or user manual. QIAGEN kit handbooks and user manuals are available at www.qiagen.com or can be requested from QIAGEN Technical Services or your local distributor.
Social Sharing